Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: A clinical trial based on a pharmacodynamic model

Journal of Chemotherapy

Volumn 14, Issue 6, 2002, Pages 591-596

  Jasovich, A ^a,b   Soutric, J ^c   Morera, G ^d   Mastruzzo, M ^a   Vesco, E ^d,e   Izaguirre, M ^d,e   Mobilia, L ^f   Prieto, S ^a,b   Franco, D ^d   Curcio, D ^a,b   Absi, R ^b   Larrateguy, L ^d   Bustos, J L ^d   Oliva, M E ^d   Arenoso, H ^c   Bantar, Carlos E ^d,f  

^a Hospital Zonal General de Agudos Dr Carlos Bocalandro   (Argentina)

^b Sanatorio Guemes   (Argentina)

^c Laboratorios Bago   (Argentina)

^d HOSPITAL SAN MARTÍN   (Argentina)

^e Sanatorio Río   (Argentina)

^f Laboratorio Domingo I Nanni   (Argentina)

Author keywords

Amoxicillin sulbactam; Pneumonia; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS SULBACTAM; ANTIBIOTIC AGENT; TRIFAMOX; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAEMOPHILUS INFLUENZAE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; RASH; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 12244294477     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.6.591     Document Type: Article

References (28)

1. National Center for Health Statistics. National hospital discharge survey: annual summary 1990. Vital Health Stat 1998; 13: 1-225.
2. Niederman MS, Peter SP. Update in pulmonary medicine. Ann Intern Med 1998; 128: 208-15.
3. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996; 275: 134-41.
4. Pomilla PV, Brown RB. Outpatient treatment of community-acquired pneumonia in adults. Arch Intern Med 1994; 154: 1793-802.
5. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82.
6. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-408.
7. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 3: 38-44.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameter: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1997; 26: 1-12.
9. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42: 2375-9.
10. Bantar C, Nicola F, Fernandez Canigia L, et al. A pharmacodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. J Chemother 2000; 12: 223-7.
11. Bantar C, Nicola F, Fernandez Canigia L, et al. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through a pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms. J Chemother 2001; 13: 402-6.
12. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
13. th ed Washington, DC: American Society for Microbiology Press, 1999.
14. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia. Etiology, epidemiology and outcome at a teaching hospital in Argentina. Chest 2000; 118: 1344-54.
15. Calmaggi A, Clara L, Gonzalez Arzac M, Lopez Furst MJ, Levy Hara G. Guias para el diagnóstico y tratamiento de la neumonía adquirida en la comunidad en adultos. Infect Microbiol Clin 2000; 12: S6-S30.
16. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383-421.
17. Huchon G and European Study on Community-acquired Pneumonia. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-91.
18. Woodhead M. Community-acquired penumonia guidelines. An international comparison. Chest 1998; 113: S183-7.
19. Joshi N, Miller DQ. Doxycycline revisited. Arch Inter Med 1997; 157: 1421-8.
20. Tice AD. Doxycycline: new ways to use an old antibiotic [letter]. Arch Inter Med 1998; 158: 928-9.
21. Kelley M, Weber D, Guilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.
22. Lisby G, Brasholt M, Teglbjerg L. Bacteremia and meningitis caused by a macrolide-sensitive strains of Streptococcus pneumoniae during treatment with azithromycin. Clin Infect Dis 2001; 33: 415-6.
23. File TM, Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34: S17-S26.
24. Calver A, Walsh N, Quinn P, et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24: 570-4.
25. Jacobs E. Serological diagnosis of Mycoplasma pneumoniae infections: a critical review of current procedures. Clin Infect Dis 1993; 17: S82-S89.
26. Petitjean J, Vabret A, Gourin S, Freymuth F. Evaluation of four commercial Immunoglobulin G (IgG)- and IgM-specific enzyme immunoassays for diagnosis of Mycoplasma pneumoniae infections. J Clin Microbiol 2002; 40:165-71.
27. Bourke SJ. Chlamydial respiratory infections. Common but difficult to diagnose. BMJ 1993; 306: 1219-20.
28. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492-503.